Strengthening regionally focused sales and marketing structures

「Europe is a region where the introduction of new products takes time due to revisions to pharmaceutical regulations and other factors. We are nevertheless working to strengthen relationships with physicians and our sales capabilities, with the aim of expanding our market share and revenue.」

「April 2025: Established 朝日英達医療器械（南寧）有限公司 in China, now a consolidated subsidiary. Opened a regional headquarters in Saudi Arabia.」

「Medical business sales performed well and increased, due to continued market-share gains in all regions and the favorable foreign-exchange impact of stronger foreign currencies.」

「In some parts of the European market, the company has been gradually shifting to direct sales, moving to direct sales in France from July 2019, Germany from January 2021, and Italy from July 2021.」

「The Group currently supplies products to 118 countries and regions worldwide.」

「As measures toward achieving this, during the three months ended the first quarter, we entered into ① a basic agreement for the exclusive distribution in Japan of Penumbra Inc.’s (U.S.) thrombus aspiration devices for peripheral vessels, ② an exclusive distribution agreement in China for DK MEDTECH (Suzhou) Co., Ltd.’s “DK Score coronary scoring balloon dilatation catheter,” and ③ issued the Group’s first “Integrated Report 2022.”」

「In overseas markets, market sizes in all regions, which had contracted due to the COVID-19 pandemic, were recovering year on year. In addition, sales increased due to higher market demand, the effects of the acquisitions of KARDIA S.R.L. and Rev1. Engineering, Inc., and the promotion of direct sales in Germany. As a result, performance was very strong, led by PTCA guidewires and penetration catheters in the cardiovascular field.」

「In some parts of the European and Middle Eastern markets, the company has been gradually shifting to direct sales, moving to direct sales in France from July 2019 and in Germany from January 2021. In addition, it acquired a distributor in Italy in July 2021 and shifted to direct sales there.」

「As measures to achieve this, during the first nine months of the current consolidated fiscal year: ① to strengthen sales and marketing activities, the company began direct sales of cardiovascular products in South Korea in July 2020; ② likewise, it began direct sales of cerebrovascular products in the United States in January 2021; and ③ likewise, it began direct sales in Germany in January 2021.」

「As measures to achieve this, during the first six months of the current consolidated fiscal year: ① to strengthen sales and marketing activities, the company began direct sales of cardiovascular products in South Korea in July 2020; ② likewise, it decided to begin direct sales of cerebrovascular products in the United States from January 2021; and ③ likewise, it established a German subsidiary (ASAHI INTECC Deutschland GmbH) in preparation for beginning direct sales in Germany from January 2021.」

「As measures to achieve this, during the first nine months of the current consolidated fiscal year, the company began direct sales in South Korea to strengthen sales and marketing activities and established a German subsidiary in preparation for beginning direct sales in Germany in January 2021.」

「The Group currently supplies products to 110 countries and regions worldwide. As part of this effort, it has been gradually introducing direct sales in France since July 2019 and plans to shift to direct sales in Germany from January 2021.」

「In addition, to strengthen sales and marketing activities, the company gradually began direct sales in France, decided to shift to direct sales in South Korea, established EU and Russian subsidiaries (ASAHI INTECC EUROPE B.V. and ASAHI INTECC CIS LLC), and opened a Guangzhou office of 朝日英達科貿(北京)有限公司 in the Chinese market.」

「In addition, to strengthen sales and marketing activities, the company gradually began direct sales in France, decided to establish a local subsidiary in Russia, and opened a Guangzhou office of 朝日英達科貿(北京)有限公司 in the Chinese market.」

「April 2019: Opened the France Branch (Paris, France). May 2019: Opened the Taiwan Branch (New Taipei City, Taiwan).」

「As measures toward achieving this, during the nine months ended the third quarter, we began direct sales of our core PTCA guidewires in the U.S. market; acquired shares in U.S.-based RetroVascular, Inc. (Note), which has plasma energy technology, making it a sub-subsidiary; acquired all shares of フィカス株式会社, a company certified for Type A continuous employment support, making it a non-consolidated subsidiary after the acquisition; completed construction of the Global Headquarters and R&D Center and relocated the head office to enhance research and development functions; entered into an exclusive distribution agreement for cerebrovascular products in the U.S. market; entered into a basic agreement concerning endoscopic devices for biliopancreatic procedures; and established a branch in France and decided to shift to direct sales, thereby further reinforcing the Group’s strengths.」

「The Group currently supplies products to 108 countries and regions worldwide. By further strengthening sales and marketing functions in each region, it intends to reinforce its earnings base on a global scale.」

「In the domestic market, product groups, primarily in the cardiovascular field and sold directly, performed well.」

「In the domestic market, product groups, primarily in the cardiovascular field and sold directly, performed well.」

「The Group currently supplies products to more than 108 countries and regions worldwide.」

「During the first 3 quarters of the current fiscal year, the Company’s consolidated subsidiary ASAHI INTECC LATIN LTDA., which sells medical business products and provides related services, increased.」

「The Group currently supplies products to more than 106 countries and regions worldwide. By further enhancing its sales and marketing functions in each region, it intends to strengthen its earnings base on a global scale.」